Biotech companies are using artificial intelligence as a risk communication tool to convince investors they can succeed, not just as a drug discovery accelerator. After only eight biotechs went public in 2025 (the lowest number in the post-pandemic era), the sector is experiencing a dramatic rebound in 2026, with experts pointing to AI as a primary driver of renewed investor confidence. The shift represents a fundamental change in how startups pitch themselves and how investors evaluate clinical-stage risk.

Why Did Biotech IPOs Collapse in 2025?

The biotech sector faced a perfect storm in 2025. Limited capital availability, elevated interest rates, and general market caution created a hostile environment for going public. But according to industry observers, the real problem ran deeper than macro conditions. Investors lacked what Tyrone Lam, chief business officer at GATC Health (an AI-focused biotech company), calls "any reliable signal" about a startup's likelihood of success. For generalist investors accustomed to data-driven decision-making in other sectors, the opacity of drug development risk made backing investigational therapies feel too uncertain to price with confidence .

This created a vicious cycle: startups couldn't raise capital, so they couldn't go public, and the IPO market remained frozen. The question wasn't whether biotech was worth investing in, but whether investors had the tools to evaluate it rationally.

How Is AI Changing the Investment Calculus?

Enter artificial intelligence. Rather than replacing human judgment, AI is making risk quantifiable. Drugmakers can now use machine learning models to optimize critical aspects of drug development before they ever enter the clinic. These include:

• Patient Selection: AI models predict the right patient populations for trials, refining inclusion criteria and forecasting trial outcomes with greater accuracy than traditional methods.
• Program Design: AI can optimize dosage strategies, enrollment timelines, and other variables that affect a drug's chances of success in human testing.
• Risk Quantification: Companies can now build what Lam calls "a structured, defensible view of how the asset is likely to behave across its development lifecycle," giving investors concrete data instead of storytelling.
• Biomarker Discovery: Machine learning models analyze massive biological and clinical datasets to identify genomic patterns and novel therapeutic targets that might have been missed by traditional approaches.

The result is a dramatic shift in how startups present themselves. "The companies drawing the most serious investor attention right now, regardless if they've IPO'd, share a common characteristic: they're using AI not just as a discovery accelerator, but as a risk communication tool," Lam explained .

What Do the 2026 IPO Numbers Actually Show?

The rebound is already visible. Several major biotechs have gone public this year with AI as a central pillar of their pitch. Generate:Biomedicines raised $425 million in February 2026, the largest biotech IPO since 2024, using an AI-heavy platform that learns from high volumes of biological data to design novel therapeutic proteins . Eikon Therapeutics raised $381 million in February by integrating AI and advanced automation into its protein tracking workflow. Aktis Oncology closed a $318 million IPO in January, highlighting how AI helps select the best radiopharmaceutical targets .

What makes Generate:Biomedicines particularly significant is that it represents what tech strategist Igor Pejic calls "the first real moment of fusion between biotech and AI." Unlike earlier AI-in-biotech stories, Generate is coming public with a late-stage asset (GB-0895, an antibody for severe asthma) and multiple clinical programs already in human testing. This signals to investors that AI-driven discovery can actually produce viable drugs, not just theoretical promise .

How to Evaluate AI-Driven Biotech Startups as an Investor

If you're considering backing an AI-focused biotech or evaluating one as an investment opportunity, experts suggest focusing on these key factors:

• Platform Maturity: Look for companies that have built AI infrastructure early, before they needed it for investor pitches. Startups that develop bespoke platforms for specific purposes (simulating human biology, predicting drug interactions, analyzing genomic data) are more credible than those bolting "AI-powered" labels onto existing workflows.
• Clinical Evidence: The most compelling AI stories pair advanced technology with actual clinical programs. A company with AI-optimized trials already underway is more convincing than one with only computational results. Generate:Biomedicines' late-stage asset and multiple ongoing studies exemplify this approach.
• Data Foundations: Ardy Arianpour, CEO of SEQSTER (an AI-driven healthcare data company), emphasizes that "investors increasingly look for organizations that pair scientific excellence with the data foundations needed for AI to deliver meaningful, repeatable insights." Ask whether the company has access to large, high-quality datasets and whether their models are trained on real-world clinical information .
• Risk Quantification Capability: The startups gaining the most traction can articulate specific, data-backed predictions about their assets' behavior. They move "from storytelling to evidence architecture," as Lam puts it, providing structured views of how a drug is likely to perform across its entire development lifecycle.

Arianpour noted that this approach "signals a systematic and scalable approach to discovery, rather than relying on traditional trial-and-error method" . For investors, that's the real value proposition of AI in biotech: not faster discovery, but smarter, more predictable development.

Arianpour

What's Different About This AI Wave Compared to Past Tech Promises?

Healthcare has seen technology revolutions before. Seventeen years ago, the federal government invested $36 billion in electronic health records (EHRs) through the HITECH Act, expecting them to revolutionize efficiency and reduce costs. While EHRs did achieve widespread adoption (86% of office-based physicians and 96% of hospitals by 2017), the results were mixed. Physicians ended up spending more time on EHRs than with patients, interoperability remained poor, and the biggest winners were EHR vendors rather than patients or the healthcare system overall .

The AI revolution in biotech is unfolding very differently. Rather than government subsidies driving adoption, the private sector is leading the charge. Hyperscalers like Alphabet, Amazon, Meta, and Microsoft are projected to spend $670 billion on AI infrastructure in 2026 alone, more than 10 times the Apollo space program as a percentage of gross domestic product . Healthcare, accounting for roughly one-fifth of the U.S. economy, has become the primary target of these investments. Digital health startups with any AI component captured 62% of all venture funding in 2025 .

This private-sector leadership creates what Ken Perez, writing for the Healthcare Financial Management Association, calls "the refining fire of market competition." Unlike the EHR era, where government mandates and subsidies drove adoption regardless of outcomes, AI adoption in biotech is driven by genuine competitive advantage. Companies that can't deliver real value won't survive. Market consolidation is inevitable, but the winners will be those whose AI actually improves drug development .

Are Hospitals Actually Using AI Yet?

While the biotech IPO story focuses on drug discovery, AI adoption in clinical settings is also accelerating. In 2024, 71% of hospitals reported using predictive AI integrated into their electronic health records. For generative AI (the type of AI behind ChatGPT-like systems), 31.5% of non-federal U.S. hospitals reported using it in 2024, with another 24.7% planning to adopt it within one year . If those plans materialized, roughly half of all non-federal hospitals in the U.S. would be using generative AI by the end of 2025.

This adoption is happening without federal subsidies, which distinguishes it sharply from the EHR rollout. Hospitals are investing in AI because they see direct operational benefits, whether through improved diagnostic accuracy, streamlined administrative workflows, or better clinical decision support. The lack of government mandates means adoption is slower but potentially more sustainable, since only genuinely useful tools survive.

What Happens If AI Biotech Companies Fail?

One legitimate concern is market consolidation. An AI leader at one of the hyperscalers recently told Perez that consolidation is inevitable as the market matures. This poses real risks for healthcare providers: if an AI vendor ceases operations, hospitals and biotech companies could be left with unsupported software and outdated models .

However, this risk is not unique to AI. The same consolidation occurred with EHRs, and healthcare adapted. What's different is that the AI revolution has more staying power. The private sector's investment dwarfs the federal government's capacity, and market competition will ruthlessly eliminate solutions that don't work. That's a more reliable mechanism for long-term success than government subsidies ever were.

The biotech IPO rebound of 2026 signals that investors have finally found a way to evaluate clinical-stage risk rationally. AI isn't just accelerating drug discovery; it's making the entire development process more transparent, predictable, and investable. For a sector that spent 2025 in the doldrums, that's a profound shift.